Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine-Reference-Cited by-同舟云学术

Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine

Published:2019-08-10 Issue:10 Volume:118 Page:3077-3084
ISSN:0932-0113
Container-title:Parasitology Research
language:en
Short-container-title:Parasitol Res

Author:

Carregal Virgínia M.,Lanza Juliane S.,Souza Daniel M.,Islam Arshad,Demicheli Cynthia,Fujiwara Ricardo T.,Rivas Luis,Frézard Frédéric^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Insect Science,General Veterinary,General Medicine,Parasitology

Link

http://link.springer.com/content/pdf/10.1007/s00436-019-06419-2.pdf

Reference27 articles.

1. Barioni MB, Ramos AP, Zaniquelli MED, Acuña AU, Ito AS (2015) Miltefosine and BODIPY-labeled alkylphosphocholine with leishmanicidal activity: aggregation properties and interaction with model membranes. Biophys Chem 196:92–99. https://doi.org/10.1016/j.bpc.2014.10.002

2. De La Torre BG, Hornillos V, Luque-Ortega JR, Abengózar MA, Amat-Guerri F, Ulises Acuña A, Rivas L, Andreu D (2014) A BODIPY-embedding miltefosine analog linked to cell-penetrating Tat(48-60) peptide favors intracellular delivery and visualization of the antiparasitic drug. Amino Acids 46:1047–1058. https://doi.org/10.1007/s00726-013-1661-3

3. Do Monte-Neto RL, Coelho AC, Raymond F, Légaré D, Corbeil J, Melo MN, Frézard F, Ouellette M (2011) Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl Trop Dis 5:1167–1176. https://doi.org/10.1371/journal.pntd.0001167

4. Duarte MC, Lage DP, Martins VT, Chávez-Fumagalli MA, Roatt BM, Menezes-Souza D, Goulart LR, Soto M, Tavares CAP, Coelho EAF (2016) Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. Rev Soc Bras Med Trop 49:398–407. https://doi.org/10.1590/0037-8682-0120-2016

5. Fernandes FR, Ferreira WA, Campos MA, Ramos GS, Kato KC, Almeida GG, Corrêa JD, Melo MN, Demicheli C, Frézard F (2013) Amphiphilic antimony (V) complexes for oral treatment of visceral leishmaniasis. Antimicrob Agents Chemother 57:4229–4236. https://doi.org/10.1128/AAC.00639-13

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of the Effect of N-(2-Methoxyphenyl)-1-methyl-1H-benzimidazol-2-amine, Compound 8, against Leishmania mexicana and Its In Vivo Leishmanicidal Activity;International Journal of Molecular Sciences;2024-01-04

2. Supramolecular assemblies from antimony(V) complexes for the treatment of leishmaniasis;Biophysical Reviews;2023-06-06

3. The novel treatments based on tissue engineering, cell therapy and nanotechnology for cutaneous leishmaniasis;International Journal of Pharmaceutics;2023-02

4. Nanoassemblies from Amphiphilic Sb Complexes Target Infection Sites in Models of Visceral and Cutaneous Leishmaniases;Pharmaceutics;2022-08-21

5. Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes;Pharmaceutics;2022-05-05